A
AVBT
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, AVBT has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +43% growth.
Stocks Performance
AVBT vs S&P TSX Composite Index (Canada)
Performance Gap
AVBT vs S&P TSX Composite Index (Canada)
Performance By Year
AVBT vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Avisa Diagnostics Inc
Glance View
Avisa Diagnostics, Inc. is a clinical stage medical device company. The company is headquartered in Santa Fe, New Mexico. The company went IPO on 2010-02-16. The firm develops the Avisa BreathTest, a drug/device biomarker technology platform that enables the detection of bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates. The firm conducts trials in cystic fibrosis, tuberculosis and community-acquired pneumonia. Its drug/device is in late-stage clinical development, which measures the lung and live organisms. The firm develops, AVISARTM instrument, which contains a touchscreen operator interface, nebulizer controller, breath sampling pneumatics and a laser spectrometer. Its Avisa BreathTest kit contains lyophilized AV-U13 drug, pre-filled syringe of sterile water, breath collection and biologic filter components and aerogen solo mesh nebulizer.
